Skip to main content
/ Impacting Human Health: Reflecting on...
25 June 2024

Impacting Human Health: Reflecting on Moderna’s Third Annual ESG Report

Shannon Thyme Klinger, Chief Legal Officer and President of the Moderna Foundation
Moderna - IR Insights - ESG Report-

As we continue to make progress in our platform and increase our potential to profoundly impact human health, we recognize that building the best version of Moderna requires increasing trust with stakeholders, protecting the health of the planet, and deeply caring for our employees and communities. By meeting at the intersection of science and responsibility, I know that we can deeply impact the lives of patients.

This week, we published our third annual Environmental, Social and Governance (ESG) Report – a milestone that underscores our commitment to transparency, stakeholder engagement and integrating ESG priorities into the heart of our operations. In its compilation, I had the chance to reflect on the incredible progress we’ve made over the last few years.

As a company, our focus remains on innovation, sustainability and making a significant positive impact on human health globally. We believe Moderna could become one of the most impactful healthcare companies, and this wouldn’t be possible without our colleagues who have the deepest sense of purpose and responsibility for our Mission.

This year’s report highlights significant advancements, including impacting more than 100 million lives globally through our mRNA medicines.

  • We have expanded our development pipeline across respiratory diseases, oncology and rare diseases, and forged a strategic partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to bolster pandemic preparedness.

  • Our mRNA Access program, which now includes 18 institutions, underscores our commitment to advancing mRNA science and supporting the next generation of researchers.

  • Additionally, we have achieved remarkable progress in clinical trial diversity, with an average enrollment of 38% Global Ethnic Majority participants in U.S. infectious disease trials.

  • In 2023, the Moderna Charitable Foundation donated $7.2 million in grants, from which $1.4 million were destined to respond to humanitarian crises after disaster events.

Looking ahead, our focus remains on advancing our ESG program with integrity and purpose. We are dedicated to achieving net-zero carbon emissions in Scopes 1 and 2 by 2030 and in Scope 3 by 2045, and we will continue to foster a culture of belonging, inclusion, and diversity. Our commitment to sustainability will guide the design of all new sites, and we will deepen our community engagement efforts to help close the inequality gap. And we will accomplish this by continuing to more deeply engage, listen and understand the expectations that our stakeholders have for us as a responsible business and leader in mRNA medicines.

Forward-Looking Statements

This post and the accompanying video contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna’s ability to enable pandemic preparedness, including its efforts targeting pandemic influenza; Moderna’s manufacturing capabilities; Moderna’s environmental sustainability strategy, including its commitment to achieving net-zero carbon emissions in Scopes 1 and 2 by 2030 and in Scope 3 by 2045; and Moderna’s ability to leverage AI. The forward-looking statements in this post and video are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this post and video in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this post.